Division of Experimental Retinal Therapies, Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Waisman Center, University of Wisconsin-Madison, Madison, WI 53705, USA; McPherson Eye Research Institute, University of Wisconsin-Madison, Madison, WI 53705, USA.
Stem Cell Reports. 2022 Aug 9;17(8):1824-1841. doi: 10.1016/j.stemcr.2022.06.009. Epub 2022 Jul 28.
Regenerative therapies aimed at replacing photoreceptors are a promising approach for the treatment of otherwise incurable causes of blindness. However, such therapies still face significant hurdles, including the need to improve subretinal delivery and long-term survival rate of transplanted cells, and promote sufficient integration into the host retina. Here, we successfully delivered in vitro-derived human photoreceptor precursor cells (PRPCs; also known as immature photoreceptors) to the subretinal space of seven normal and three rcd1/PDE6B mutant dogs with advanced inherited retinal degeneration. Notably, while these xenografts were rejected in dogs that were not immunosuppressed, transplants in most dogs receiving systemic immunosuppression survived up to 3-5 months postinjection. Moreover, differentiation of donor PRPCs into photoreceptors with synaptic pedicle-like structures that established contact with second-order neurons was enhanced in rcd1/PDE6B mutant dogs. Together, our findings set the stage for evaluating functional vision restoration following photoreceptor replacement in canine models of inherited retinal degeneration.
旨在替代光感受器的再生疗法是治疗其他无法治愈的失明原因的一种有前途的方法。然而,这些疗法仍然面临着重大障碍,包括需要提高视网膜下的递呈和移植细胞的长期存活率,并促进其与宿主视网膜的充分整合。在这里,我们成功地将体外衍生的人类光感受器前体细胞(PRPCs;也称为未成熟光感受器)递送到 7 只正常和 3 只 rcd1/PDE6B 突变犬的视网膜下腔,这些犬患有晚期遗传性视网膜变性。值得注意的是,虽然这些异种移植物在未接受免疫抑制的犬中被排斥,但在大多数接受全身免疫抑制的犬中,移植物在注射后长达 3-5 个月存活下来。此外,在 rcd1/PDE6B 突变犬中,供体 PRPCs 分化为具有与二级神经元建立接触的突触足样结构的光感受器的能力增强。总之,我们的发现为在遗传性视网膜变性的犬模型中评估光感受器替代后功能性视力恢复奠定了基础。